A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
Launched by SANTEN INC. · Sep 28, 2018
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • glaucoma or ocular hypertension
- Exclusion Criteria:
- • Females who are pregnant, nursing, or planning a pregnancy
- • Any corneal abnormality or other condition interfering with or preventing reliable tonometric measurements
About Santen Inc.
Santen Inc. is a global pharmaceutical company dedicated to the research, development, and commercialization of innovative ophthalmic products. With a strong focus on addressing unmet medical needs in eye care, Santen leverages its extensive expertise in the field to enhance the quality of life for patients suffering from various ocular conditions. Committed to advancing science and improving patient outcomes, Santen Inc. collaborates with healthcare professionals and stakeholders worldwide to deliver effective therapies and promote vision health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cleveland, Ohio, United States
Stuart, Florida, United States
Gainesville, Florida, United States
Virginia Beach, Virginia, United States
Kansas City, Missouri, United States
Rochester, New York, United States
Havre De Grace, Maryland, United States
Glendale, California, United States
Memphis, Tennessee, United States
Chandler, Arizona, United States
Ormond Beach, Florida, United States
San Antonio, Texas, United States
Morrow, Georgia, United States
San Diego, California, United States
Las Vegas, Nevada, United States
Asheville, North Carolina, United States
Memphis, Tennessee, United States
Salt Lake City, Utah, United States
Prescott, Arizona, United States
Inglewood, California, United States
Newport Beach, California, United States
Petaluma, California, United States
Sacramento, California, United States
Westminster, California, United States
Colorado Springs, Colorado, United States
Largo, Florida, United States
Saint Joseph, Michigan, United States
Independence, Missouri, United States
Washington, Missouri, United States
Dallas, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
League City, Texas, United States
Roanoke, Virginia, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials